Annals of Internal Medicine, Volume 177, Issue 9, Page 1292, September 2024.
Risultati per: Le campagne di screening come strumento di prevenzione oncologica tra dubbi e certezze
Questo è quello che abbiamo trovato per te
The New Proposed U.S. Preventive Services Task Force Recommendation on Breast Cancer Screening for Women in Their 40s
Annals of Internal Medicine, Volume 177, Issue 9, Page 1292-1293, September 2024.
The New Proposed U.S. Preventive Services Task Force Recommendation on Breast Cancer Screening for Women in Their 40s
Annals of Internal Medicine, Volume 177, Issue 9, Page 1293-1294, September 2024.
The New Proposed U.S. Preventive Services Task Force Recommendation on Breast Cancer Screening for Women in Their 40s
Annals of Internal Medicine, Volume 177, Issue 9, Page 1293-1294, September 2024.
The New Proposed U.S. Preventive Services Task Force Recommendation on Breast Cancer Screening for Women in Their 40s
Annals of Internal Medicine, Volume 177, Issue 9, Page 1294, September 2024.
The New Proposed U.S. Preventive Services Task Force Recommendation on Breast Cancer Screening for Women in Their 40s
Annals of Internal Medicine, Volume 177, Issue 9, Page 1292-1293, September 2024.
The New Proposed U.S. Preventive Services Task Force Recommendation on Breast Cancer Screening for Women in Their 40s
Annals of Internal Medicine, Volume 177, Issue 9, Page 1291-1292, September 2024.
The New Proposed U.S. Preventive Services Task Force Recommendation on Breast Cancer Screening for Women in Their 40s
Annals of Internal Medicine, Volume 177, Issue 9, Page 1294, September 2024.
Screening for Iron Deficiency and Iron Deficiency Anemia During Pregnancy
This JAMA Patient Page discusses the pros and cons of screening for iron deficiency and iron deficiency anemia during pregnancy.
USPSTF Review: Screening and Supplementation for Iron Deficiency During Pregnancy
This systematic review to support a 2024 US Preventive Services Task Force Recommendation Statement summarizes published evidence on the benefits and harms of iron supplementation, and screening for iron deficiency and iron deficiency anemia, during pregnancy.
The New Proposed U.S. Preventive Services Task Force Recommendation on Breast Cancer Screening for Women in Their 40s
Annals of Internal Medicine, Volume 177, Issue 9, Page 1292, September 2024.
Transcranial Doppler With Microbubbles: Screening Test to Detect and Grade Right-to-Left Shunt After an Ischemic Stroke: A Literature Review
Stroke, Ahead of Print. Right-to-left shunt, mainly due to patent foramen ovale (PFO), is likely responsible for ≈5% of all ischemic strokes and 10% of those occurring in young and middle-aged adults. Randomized clinical trials demonstrated that, in selected young and middle-aged patients with otherwise cryptogenic acute ischemic stroke and high-risk PFO, percutaneous PFO closure is more effective than antiplatelet therapy alone in preventing recurrence. However, PFO is generally a benign finding and is present in about one-quarter of the population. Therefore, in clinical practice, identifying PFOs that are likely to be pathogenetic is crucial for selecting suitable patients for PFO closure to prevent recurrent stroke and to avoid potentially harmful and costly overtreatment. Contrast transthoracic echocardiography has a relatively low sensitivity in detecting PFO, whereas transesophageal echocardiography is currently considered the gold standard for PFO detection. However, it is a relatively invasive procedure and may not always be easily feasible in the subacute setting. Contrast transcranial Doppler is a noninvasive, inexpensive, accurate tool for the detection of right-to-left shunt. We conducted a literature review on the use of contrast transcranial Doppler to detect and grade right-to-left shunt after an acute ischemic stroke and present a clinical workflow proposal for young and middle-aged patients.
Are Commonly Used Fecal Immunochemical Tests for Colorectal Cancer Screening Created Equal?
No. Test performance is quite variable.
Guideline concordant screening and monitoring of extrapyramidal symptoms in patients prescribed antipsychotic medication: a protocol for a systematic literature review and narrative synthesis
Introduction
Given the increasing rates of antipsychotic use in multiple psychiatric conditions, greater attention to the assessment, monitoring and documentation of their side effects is warranted. While a significant degree of attention has been provided to metabolic side effect monitoring, comparatively little is known about how clinicians screen for, document and monitor the motor side effects of antipsychotics (ie, parkinsonism, akathisia, dystonia and dyskinesias, collectively ‘extrapyramidal side effects’, EPS). This review aims to systematically assess the literature for insights into current trends in EPS monitoring practices within various mental health settings globally.
Methods and analysis
An electronic search will be performed using the OVID Medline, PubMed, Embase, CINAHL and APA PsycINFO databases for studies published in the last quarter century (1998 to present day). Two independent reviewers will conduct the initial title and abstract screenings, using predetermined criteria for inclusion and exclusion. A third reviewer will resolve disagreements if consensus cannot be reached. If selected for inclusion, full-text data extraction will then be conducted using a pilot-tested data extraction form. Quality assessment will be conducted for all included studies using a modified version of the Quality Improvement Minimum Quality Criteria Set. A narrative synthesis and summary of the data will be provided. All stages of the review process will be reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
Ethics and dissemination
Ethical approval is not required. Findings will be peer reviewed, published and shared verbally, electronically and in print with interested clinicians and will also be presented as posters or talks at relevant medical conferences and meetings.
PROSPERO registration number
CRD42023482372.
Screening instruments for mental disorders in primary healthcare: a scoping review protocol (SCREENING-MD)
Introduction
When mental disorders go undetected until later stages, they can result in poorer health outcomes for patients. Primary healthcare (PHC) stands as a strategic setting for the early identification and management of these mental disorders, given its role as the primary care environment for health service users. This scoping review has the objective of mapping and assessing screening instruments validated for mental disorders that are applicable in PHC, particularly regarding their measurement properties.
Methods and analysis
This scoping review will include studies that have developed and validated screening instruments for mental disorders in the PHC context, irrespective of the age group. Searches will be conducted in MEDLINE, EMBASE, LILACS, CINAHL and PsycInfo without imposing restrictions on publication status, publication year or language. Additionally, we will scrutinise the references cited in the selected studies. Our inclusion criteria encompass studies examining any measurement property recommended by the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) taxonomy. The selection process, data extraction and quality assessment of studies will be performed independently by pairs of reviewers. To evaluate the risk of bias within the selected studies, we will employ the COSMIN Risk of Bias 2 tools. The collected data will undergo analysis using descriptive statistics and will be presented in an evidence gap map format for each specific mental disorder.
Ethics and dissemination
The findings from this review will be discussed through deliberative dialogue with stakeholders and disseminated through peer-reviewed publications and conference presentations. The project was approved by the Ethics Committee for Research at the University of Sorocaba (number: 66993323.9.0000.5500).
Trial registration number
Open Science Framework – 10.17605/OSF.IO/Z6T5M.
Ast, prosegue a Castelfidardo screening gratis per epatite C
In provincia di Ancona già eseguiti più di 15mila prelievi